Track market-moving stories before they get noisy

July 22, 2026 06:00 ET  | Source: RadNet, Inc.

LOS ANGELES, July 22, 2026 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, cost-effective diagnostic imaging services through a network of owned and operated outpatient imaging centers and digital health solutions, announced today that it will host a conference call to discuss its second quarter 2026 financial results on Monday, August 10, 2026 at 7:30 a.m. Pacific Time (10:30 a.m. Eastern Time).

Investors are invited to listen to RadNet’s conference call by dialing 844-744-1280. International callers can dial 412-564-6465. There will also be simultaneous and archived webcasts available at https://viavid.webcasts.com/starthere.jsp?ei=1770869&tp_key=f4d7c2481f. An archived replay of the call will also be available and can be accessed by dialing 844-512-2921 from the U.S., or 412-317-6671 for international callers, and using the passcode 10210872.

About RadNet, Inc.
RadNet, Inc. is a leading national provider of freestanding, fixed-site diagnostic imaging services in the United States based on the number of locations and annual imaging revenue. RadNet has a network of owned and operated outpatient imaging centers. RadNet’s markets include Arizona, California, Delaware, Florida, Idaho, Indiana, Maryland, New Jersey, New York, Texas and Virginia. In addition, RadNet provides radiology information technology and artificial intelligence solutions marketed under the DeepHealth brand, teleradiology professional services and other related products and services to customers in the diagnostic imaging industry. Together with contracted radiologists, and inclusive of full-time and per diem employees and technologists, RadNet has a total of over 11,000 employees. For more information, visit http://www.radnet.com.

CONTACTS:

RadNet, Inc.
Mark Stolper
Executive Vice President and Chief Financial Officer
310-445-2800

Key Takeaways RadNet's DeepHealth received FDA clearances for BAC Assessment and Mammo Dx functionalities.BAC Assessment detects breast arterial calcifications on 2D and 3D screening mammograms.Mammo Dx compares current and prior mammograms to track lesion changes and reduce recalls. DeepHealth, a wholly owned subsidiary of RadNet (RDNT - Free Report) , recently received FDA clearances for two new functionalities within its AI-powered Breast Suite. The FDA clearances expand its AI-powered Breast Suite with cardiovascular risk assessment and prior exam integration, strengthening its end-to-end breast imaging platform. The approvals cover Breast Arterial Calcification (BAC) Assessment and prior exam integration into ProFound Pro, which will be marketed as Mammo Dx.

The BAC Assessment automatically detects breast arterial calcifications on standard mammograms to identify the potential risk of cardiovascular disease. Whereas Mammo Dx compares current and prior mammograms to track lesion changes, improving cancer detection and reducing patient recalls. Both functionalities are now commercially available in the United States.

Per management, DeepHealth's strategy has always focused on using AI to find disease early. The launch of BAC Assessment and Mammo Dx transforms its Breast Suite into a fully integrated suite of solutions that gives radiologists a complete patient overview and adds clinical confidence in the top causes of death in U.S. women.

Likely Trend of RDNT Stock Following the News

Shares of RDNT have gained 1.2% since the announcement on Thursday. Year to date, the stock has declined 14.9%, underperforming the industry’s 14.3% growth and the S&P 500’s 7.4% rise.

The FDA clearance of BAC Assessment and Mammo Dx is positive for RadNet as it expands DeepHealth's AI-powered breast imaging portfolio and strengthens its competitive position. The new solutions enhance cancer detection and cardiovascular risk assessment and improve radiologist decision-making without additional imaging. In addition, deployment across RadNet's imaging centers will generate real-world validation, support broader customer adoption and reinforce the company's AI-driven growth strategy.

RDNT currently has a market capitalization of $4.78 billion.

Image Source: Zacks Investment Research

More on the FDA-Cleared Functionalities

BAC Assessment automatically identifies breast arterial calcifications on both standard 2D (FFDM) and 3D (DBT) screening mammograms without requiring additional imaging. These calcifications have been associated with an increased risk of future cardiovascular events such as heart attacks and strokes.

In clinical testing, the assessment demonstrated more than 90% sensitivity and over 88% specificity across dense and non-dense breast tissue. The assessment will be deployed across RadNet imaging centers for real-world validation.

Mammo Dx enables radiologists to analyze current and prior mammograms together, helping identify subtle tissue changes and undetected lesions in a single examination. By incorporating historical findings into the diagnostic workflow, the solution aims to improve cancer detection, reduce false-positive recalls and support more informed clinical decision-making.

With these additions, DeepHealth's Breast Suite offers a comprehensive AI platform supporting cancer detection, cardiovascular risk assessment, breast density evaluation, future cancer risk assessment and workflow optimization. So far, components of Breast Suite support diagnostic accuracy and standardization of care across more than 10 million mammograms annually worldwide.

Industry Prospects Favoring the Market

Going by the data provided by Precedence Research, the artificial intelligence (AI) in the breast imaging market is valued at $666.9 million in 2026 and is expected to witness a CAGR of 15.9% through 2035.

Factors like increased breast cancer awareness and early detection, growing health insurance and an increasing aging population are boosting the market’s growth.

Other News

DeepHealth recently launched Reporting Pro, an AI-powered reporting solution that streamlines radiology workflows. The platform combines speech recognition, AI-generated findings and impressions, automated measurements, quality assurance and structured reporting into a single, integrated workflow for radiologists.

RDNT’s Zacks Rank & Key Picks

Currently, RDNT has a Zacks Rank #3 (Hold).

Some better-ranked stocks from the broader medical space are BrightSpring Health (BTSG - Free Report) , Globus Medical (GMED - Free Report) and West Pharmaceutical (WST - Free Report) .

BrightSpring Health, currently sporting a Zacks Rank #1 (Strong Buy), reported first-quarter 2026 adjusted earnings per share (EPS) of 39 cents, which beat the Zacks Consensus Estimate by 34.5%. Revenues of $3.61 billion surpassed the Zacks Consensus Estimate by 8.35%. You can see the complete list of today’s Zacks #1 Rank stocks here.

BrightSpring Health has an estimated long-term earnings growth rate of 46.5%. BTSG’s earnings surpassed estimates in three of the trailing four quarters and missed once, the average surprise being 14.6%.

Globus Medical, currently carrying a Zacks Rank #2 (Buy), reported a first-quarter 2026 adjusted EPS of $1.12, which surpassed the Zacks Consensus Estimate by 22.1%. Revenues of $759.9 million beat the Zacks Consensus Estimate by 4.0%.

GMED has an estimated long-term earnings growth rate of 10.2%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 26.3%.

West Pharmaceutical, carrying a Zacks Rank #2 at present, reported first-quarter 2026 EPS of $2.13, which beat the Zacks Consensus Estimate by 26.8%. Revenues of $844.9 million surpassed the Zacks Consensus Estimate by 8.5%.

West Pharmaceutical has an estimated long-term earnings growth rate of 13.9%. WST’s earnings surpassed estimates in the trailing four quarters, the average surprise being 19.4%.

On June 22, 2026, RadNet Inc RDNT shares rose 3.8% today, trading at $55.74. The stock has experienced a 52-week range of $50.76 to $85.84, reflecting volatility in its price performance.

GF Value™ verdict: Current price of $55.74 vs GF Value™ of $66.68, indicating a 16.4% undervaluation.GF Score™: 79/100, which suggests the stock is rated as above average in terms of potential for long-term returns.Most notable signal: Insiders sold $2.8M worth of shares in the last three months, indicating a lack of buying interest. Is RDNT Overvalued or Undervalued? According to the GF Value™, RadNet Inc is currently trading below its estimated fair value of $66.68, suggesting that the stock is 16.4% undervalued. This margin of safety could represent an opportunity for investors seeking undervalued stocks, but it is important to consider the caveats associated with such valuations. The GF Valuation label categorizes RadNet as "Modestly Undervalued," highlighting the potential for price appreciation, yet caution is warranted given the current market conditions and recent insider selling activity.

GF Value™ is GuruFocus' proprietary measure of intrinsic value, calculated from historical trading multiples, past business growth, and future performance estimates. In the case of RadNet, despite the undervaluation signal, investors should remain vigilant due to the company's financial strength rating of 4/10, which indicates some vulnerabilities within its financial structure.

How Does RDNT's Valuation Compare to Its History? Metric Current Historical P/E (TTM) 112.4x 110.2x RadNet's current forward P/E ratio of 112.4x is slightly above its 5-year median P/E of 110.2x, indicating that the stock is trading at a premium compared to its historical valuation. This P/E analysis aligns with the GF Value™ verdict which suggests that the stock may be undervalued when considering its intrinsic value, yet the high P/E ratio raises questions about whether the stock can sustain such valuations in the long term.

What Does RDNT's GF Score™ Tell Us? Metric Rating GF Score™ 79/100 Financial Strength 4/10 Profitability 6/10 Growth 8/10 Valuation 8/10 Momentum 5/10 The GF Score™ of 79/100 indicates that RadNet is rated above average in terms of its potential for long-term returns. The strongest area is its Growth rank of 8/10, suggesting solid growth prospects ahead. However, the Financial Strength rating of 4/10 raises some concerns about the company's ability to withstand financial pressures, which could impact its long-term viability.

What Are Insiders Doing with RDNT Stock? In the last three months, insiders of RadNet Inc have sold $2.8 million worth of shares, with no recorded buying activity. This trend of insider selling may suggest a lack of confidence among company executives regarding the stock's future performance. Insider selling can often be interpreted as a negative signal, indicating that those closest to the company may believe the stock is fully valued at current levels or are anticipating challenges ahead.

What This Means for Investors Based on the GF Value™ assessment, RadNet Inc RDNT is classified as modestly undervalued at the current price of $55.74, compared to a fair value of $66.68. However, caution is advised given the selling activity from insiders, along with the company's middling financial strength rating.

For the complete analysis, visit the RadNet Inc RDNT stock page. You can also explore the GF Value™ page for detailed valuation methodology, or use the GuruFocus Stock Screener to find similar opportunities.

Frequently Asked Questions What is RDNT's GF Score™?

RadNet Inc has a GF Score™ of 79/100, indicating the stock is rated above average in terms of potential for long-term returns.

Is RDNT overvalued or undervalued?

RadNet Inc is currently undervalued, with the GF Value™ indicating a fair value of $66.68 compared to the current price of $55.74.

What is RDNT's P/E ratio?

RadNet's forward P/E ratio is 112.4x, which is slightly above its 5-year median P/E of 110.2x, suggesting the stock is trading at a premium relative to its historical valuations.

This stock alert was generated using automated technology and GuruFocus financial data to provide readers with timely and accurate market reporting. This content was reviewed by GuruFocus editorial team prior to publication. Please send any questions or comments about this story to [email protected].

Posted by Defense World Staff on Apr 17th, 2026

Campbell Newman Asset Management Inc. purchased a new position in shares of RadNet, Inc. (NASDAQ:RDNT – Free Report) during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 24,848 shares of the medical research company’s stock, valued at approximately $1,773,000.

Several other institutional investors and hedge funds have also added to or reduced their stakes in RDNT. Allworth Financial LP lifted its position in RadNet by 346.6% during the 3rd quarter. Allworth Financial LP now owns 393 shares of the medical research company’s stock valued at $30,000 after purchasing an additional 305 shares during the period. Danske Bank A S acquired a new stake in shares of RadNet in the 3rd quarter valued at approximately $30,000. Farther Finance Advisors LLC raised its position in shares of RadNet by 1,086.5% in the 3rd quarter. Farther Finance Advisors LLC now owns 439 shares of the medical research company’s stock valued at $33,000 after acquiring an additional 402 shares during the period. Jones Financial Companies Lllp raised its position in shares of RadNet by 62.2% in the 3rd quarter. Jones Financial Companies Lllp now owns 446 shares of the medical research company’s stock valued at $34,000 after acquiring an additional 171 shares during the period. Finally, Salomon & Ludwin LLC acquired a new stake in shares of RadNet in the 3rd quarter valued at approximately $37,000. Institutional investors and hedge funds own 77.90% of the company’s stock.

Wall Street Analyst Weigh In RDNT has been the topic of a number of analyst reports. Raymond James Financial reiterated a “strong-buy” rating on shares of RadNet in a research report on Thursday, December 18th. UBS Group set a $92.00 price target on shares of RadNet in a research report on Friday, January 9th. KeyCorp upgraded shares of RadNet to a “strong-buy” rating in a research report on Friday, January 9th. Jefferies Financial Group reiterated a “buy” rating and issued a $91.00 price target on shares of RadNet in a research report on Tuesday, March 3rd. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of RadNet in a research report on Monday, December 29th. Two analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $90.43.

Check Out Our Latest Research Report on RDNT

Insider Activity In other news, insider Alma Gregory Sorensen sold 15,000 shares of the business’s stock in a transaction dated Wednesday, March 18th. The shares were sold at an average price of $62.15, for a total value of $932,250.00. Following the completion of the sale, the insider owned 1,208,923 shares of the company’s stock, valued at approximately $75,134,564.45. The trade was a 1.23% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 5.60% of the company’s stock.

RadNet Price Performance NASDAQ:RDNT opened at $60.09 on Friday. The company has a current ratio of 1.76, a quick ratio of 1.76 and a debt-to-equity ratio of 0.79. The firm has a fifty day simple moving average of $63.28 and a 200 day simple moving average of $71.52. RadNet, Inc. has a 1-year low of $46.76 and a 1-year high of $85.84. The stock has a market capitalization of $4.66 billion, a PE ratio of -240.36 and a beta of 1.53.

RadNet (NASDAQ:RDNT – Get Free Report) last announced its earnings results on Monday, March 2nd. The medical research company reported $0.23 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.19 by $0.04. The company had revenue of $547.71 million during the quarter, compared to analysts’ expectations of $515.67 million. RadNet had a negative net margin of 0.91% and a positive return on equity of 2.52%. RadNet’s quarterly revenue was up 14.8% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.22 earnings per share. On average, research analysts expect that RadNet, Inc. will post 0.56 EPS for the current fiscal year.

RadNet Company Profile (Free Report)

RadNet, Inc is a leading independent provider of outpatient diagnostic imaging services in the United States. Through a nationwide network of fixed-site imaging centers and affiliated joint-venture locations, the company delivers a comprehensive suite of radiology services including MRI, CT, PET/CT, ultrasound, X-ray, mammography, bone densitometry, nuclear medicine and interventional radiology procedures. RadNet also offers teleradiology and imaging management solutions to physician practices, hospitals and healthcare systems.

Founded in 1981 and headquartered in Los Angeles, RadNet has expanded its footprint organically and through strategic acquisitions.

Further Reading Five stocks we like better than RadNet

Receive News & Ratings for RadNet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RadNet and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINEAmphenol Corporation $APH is Campbell Newman Asset Management Inc.’s 5th Largest Position

NEXT HEADLINE »Berkeley Inc Acquires 13,140 Shares of Paycom Software, Inc. $PAYC

April 28, 2026 06:00 ET  | Source: RadNet, Inc.

LOS ANGELES, April 28, 2026 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, cost-effective diagnostic imaging services and digital health solutions, announced today that it will host a conference call to discuss its first quarter 2026 financial results on Monday, May 11, 2026 at 7:30 a.m. Pacific Time (10:30 a.m. Eastern Time).

Investors are invited to listen to RadNet’s conference call by dialing 844-744-1280. International callers can dial 412-564-6465. There will also be simultaneous and archived webcasts available at https://viavid.webcasts.com/starthere.jsp?ei=1761306&tp_key=ea5d61284c. An archived replay of the call will also be available and can be accessed by dialing 844-512-2921 from the U.S., or 412-317-6671 for international callers, and using the passcode 10208825.

About RadNet, Inc.
RadNet, Inc. is a leading national provider of freestanding, fixed-site diagnostic imaging services in the United States based on the number of locations and annual imaging revenue. RadNet has a network of owned and operated outpatient imaging centers. RadNet’s imaging center markets include Arizona, California, Delaware, Florida, Indiana, Maryland, New Jersey, New York, Texas and Virginia. In addition, RadNet provides radiology information technology and artificial intelligence solutions marketed under the DeepHealth brand, teleradiology professional services and other related products and services to customers in the diagnostic imaging industry globally. Together with contracted radiologists, and inclusive of full-time and per diem employees and technologists, RadNet has over 11,000 team members. Learn more at www.radnet.com.

CONTACTS:

RadNet, Inc.
Mark Stolper
Executive Vice President and Chief Financial Officer
310-445-2800

LOS ANGELES, April 30, 2026 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, cost-effective outpatient diagnostic imaging services and a global developer of digital health solutions, announced today the formation of a joint venture with Saint Alphonsus Health System through the acquisition of a majority equity position in Intermountain Medical Imaging, LLC, the owner of five outpatient multi-modality imaging centers in Boise, Idaho.

The Idaho-based joint venture with Saint Alphonsus Health System, which is part of Trinity Health, operates three multimodality outpatient imaging centers in Meridian and Eagle, as well as facilities at two Saint Alphonsus medical centers. The existing contracted radiology practice for the joint venture, Gem State Radiology, will continue providing professional radiology services to the five locations through its network of nearly 30 radiologists. RadNet will assume management of the operations for each of the five locations. The centers currently offer a mix of MRI, CT, PET/CT, mammography, ultrasound, X-ray and other related procedures.

Through the relationship, Gem State Radiology will deliver radiology interpretation and reporting to Saint Alphonsus Health System using DeepHealth’s solutions, including:

Diagnostics Suite: a cloud-first clinical imaging management and viewing platform, enabling fast, intuitive and highly efficient clinical interpretation.Reporting Pro: an AI-powered radiology report-creation tool to improve radiologist productivity and consistency.AI Studio: an enterprise-grade AI orchestrator for managing, routing and monitoring a growing ecosystem of AI tools.Clinical AI: FDA-cleared solutions to enhance screening, detection and interpretation across various clinical specialties, including oncology, neurology and musculoskeletal health. In addition, the five joint venture imaging centers will benefit from improved operational efficiencies through DeepHealth’s Operations Suite, a cloud-first, AI-powered suite of solutions that unifies patient, clinical and operational workflows, including:

Radiology Information System: a unified imaging operations system seamlessly connecting teams and workflows across networks.Patient Engagement: a digital-first patient engagement platform that guides each patient from scheduling through preparation, registration and follow-up.Operational AI: a portfolio of agentic solutions that intelligently automate tasks and workflows to streamline operations, improve efficiencies, and monitor and optimize imaging centers’ performance.
Together, these solutions are expected to improve efficiency and facilitate quality care.

"This relationship with Saint Alphonsus Health System marks a pivotal moment for diagnostic imaging in Idaho," said Norman Hames, President and CEO of Western Operations for RadNet. "We are bringing together the best of what each organization offers — Saint Alphonsus’s deep community roots and clinical excellence and RadNet’s broad expertise in managing outpatient operations efficiently and profitably. In addition, the integration of DeepHealth solutions addresses key industry challenges, including fragmented IT systems, diagnostic variability and workforce shortages to deliver faster, more consistent and more scalable care."

David McFadyen, President & CEO, Saint Alphonsus Health System, Trinity Health, West Region, highlighted, “The relationship with RadNet allows us to bring best-in-class outpatient imaging management, efficient workflows and AI technologies to improve both the patient journey and the service we provide to our referring physician communities. This collaboration should streamline operations and enable our care teams to focus on what matters most — delivering exceptional, compassionate care to the communities we serve.”

Jane Turlo, Vice President Ambulatory Imaging, Trinity Health, “This relationship enhances our ability to equip providers with powerful tools to provide quality care to patients throughout the region.”

The new joint venture is projected to generate approximately $30 million in annual revenue for RadNet.

About RadNet, Inc. 
RadNet, Inc. is a leading national provider of freestanding, fixed-site diagnostic imaging services in the United States based on the number of locations and annual imaging revenue.  RadNet has a network of owned and/or operated outpatient imaging centers.  RadNet’s imaging center markets include Arizona, California, Delaware, Florida, Idaho, Indiana, Maryland, New Jersey, New York, Texas and Virginia.  In addition, RadNet provides radiology information technology and artificial intelligence solutions marketed under the DeepHealth brand, teleradiology professional services and other related products and services to customers in the diagnostic imaging industry globally.  Together with contracted radiologists, and inclusive of full-time and per diem employees and technologists, RadNet has over 11,000 team members.  Learn more at radnet.com. 

About DeepHealth  
DeepHealth is a wholly owned subsidiary of RadNet, Inc. (NASDAQ: RDNT) and serves as the umbrella brand for RadNet’s Digital Health segment.  DeepHealth provides AI-powered health informatics with the aim of empowering breakthroughs in care through imaging.  DeepHealth leverages advanced AI for operational efficiency and improved clinical outcomes in breast, chest, musculoskeletal, neuro, prostate and thyroid health.  At the heart of DeepHealth’s portfolio is a cloud-native operating system – DeepHealth OS – that unifies data across the clinical and operational workflow.  Thousands of imaging centers and radiology departments around the world use DeepHealth solutions to enable earlier, more reliable and more efficient disease detection, including in large-scale cancer screening programs.  DeepHealth’s human-centered, intuitive technology aims to push the boundaries of what’s possible in healthcare. Learn more at deephealth.com. 

About Trinity Health
Trinity Health is one of the largest not-for-profit, faith-based health care systems in the nation. It is a family of 133,000 colleagues and more than 38,900 physicians and clinicians caring for diverse communities across 23 states. Nationally recognized for care and experience, the Trinity Health system includes 92 hospitals, 101 continuing care locations, the second largest PACE program in the country as well as many other health and well-being services. In fiscal year 2025, the Livonia, Michigan-based health system invested $2.9 billion in its communities in the form of charity care, community benefit and other programs and services. 

About Saint Alphonsus Health System
Saint Alphonsus Health System is a Catholic, faith-based, not-for-profit health care system serving Idaho, eastern Oregon, and northern Nevada communities. The health system, which was named a 2025 Forbes Best Large Employers of America, includes 4 hospitals, 595 licensed beds, 86 medical group clinics, and 7 joint venture relationships.  The health system employs more than 7,000 colleagues and providers.  The Saint Alphonsus Health Alliance is comprised of over 3,400 employed and independent providers.  The health system hospitals include Saint Alphonsus Regional Medical Center - Boise, ID; Saint Alphonsus Regional Rehabilitation Hospital – Boise, ID, a joint venture with Encompass Health; Saint Alphonsus Medical Center – Nampa, ID; Saint Alphonsus Medical Center – Ontario, OR; Saint Alphonsus Medical Center – Baker City, OR. Saint Alphonsus Health System reinvests in the communities we serve, through charity care and other benefits. Our goal is to improve the health and well-being of people by emphasizing care that is patient-centered, physician-led, innovative, and community-based. For more information, visit us at www.saintalphonsus.org.  Saint Alphonsus is a proud member of Trinity Health. 

About Gem State Radiology
Gem State Radiology (GSR) was established in 1974 and has served patients and providers in the Treasure Valley for more than five decades. In 1999, GSR expanded its outpatient imaging footprint by establishing Intermountain Medical Imaging, increasing access to high-quality diagnostic outpatient imaging across the region. GSR continues its longstanding commitment to physician-focused radiology services, supporting hospital and outpatient imaging needs throughout Idaho.

For more information, visit us at www.trinity-health.org or follow us on LinkedIn, Facebook and X.

Forward Looking Statements
This communication contains certain “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements can be identified by words such as: “anticipate,” “believe,” “could,” “estimate,” “expect,” “forecast,” “intend,” “may,” “outlook,” “plan,” “potential,” “possible,” “predict,” “project,” “seek, “should,” “target,” “will” or “would,” the negative of these words, and similar references to future periods. Examples of forward-looking statements include statements regarding the anticipated benefits of the acquisition, the impact of the acquisition on RadNet’s business and future financial and operating results and prospects, and the amount and timing of synergies from the acquisition are based on the current estimates, assumptions and projections of RadNet, and are qualified by the inherent risks and uncertainties surrounding future expectations generally, all of which are subject to change. Actual results could differ materially from those currently anticipated due to a number of risks and uncertainties, many of which are beyond RadNet’s control.

Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on management’s current beliefs, expectations and assumptions regarding the future of RadNet’s business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of RadNet’s control. RadNet’s actual results and financial condition may differ materially from those indicated in the forward-looking statements as a result of various factors. None of RadNet’s or Trinity Health’s respective directors, executive officers or advisors provide any representation, assurance or guarantee that the occurrence of the events expressed or implied in any forward-looking statements will actually occur, or if any of them do occur, what impact they will have on the business, results of operations or financial condition of RadNet. Should any risks and uncertainties develop into actual events, these developments could have a material adverse effect on RadNet’s business and the ability to realize the expected benefits of the acquisition. Risks and uncertainties that could cause results to differ from expectations include, but are not limited to: (1) the ability to recognize the anticipated benefits of the acquisition, which may be affected by, among other things, the ability of RadNet or Trinity Health to maintain relationships with its vendors, customers and providers and retain its management and key employees, (2) the ability to achieve the synergies contemplated by the acquisition or such synergies taking longer to realize than expected, (3) costs related to the acquisition, (4) the ability of RadNet to execute successfully its strategic plans, (5) the diversion of management’s time and attention from ordinary course business operations to integration matters, and (6) the risk of legislative, regulatory, economic, competitive, and technological changes. The foregoing review of important factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included elsewhere. Additional information concerning risks, uncertainties and assumptions can be found in RadNet’s filings with the Securities and Exchange Commission (the “SEC”), including the risk factors discussed in RadNet’s most recent Annual Report on Form 10-K, as updated by its Quarterly Reports on Form 10-Q and future filings with the SEC.

Forward-looking statements included herein are made only as of the date hereof and, except as required by applicable law, RadNet does not undertake any obligation to update any forward-looking statements, or any other information in this communication, as a result of new information, future developments or otherwise, or to correct any inaccuracies or omissions in them which become apparent. All forward-looking statements in this communication are qualified in their entirety by this cautionary statement.

RadNet Media Contacts 
Jane Mazur 
Senior Vice President, Corporate Communications 
+1 585-355-5978 
[email protected]

Mark Stolper
Executive Vice President and Chief Financial Officer
+1 310-445-2800

Total Company Revenue increased 22.1% to $575.6 million in the first quarter of 2026 from $471.4 million in the first quarter of 2025Revenue from the Digital Health reportable segment increased 51.5% to $29.1 million in the first quarter of 2026 from $19.2 million in the first quarter of 2025; Annual Recurring Revenue(4) (ARR) increased from $49.8 million at March 31, 2025 to $96.9 million at March 31, 2026Total Company Adjusted EBITDA(1) was $63.3 million in the first quarter of 2026 as compared with $46.4 million in the first quarter of 2025, an increase of 36.3%; Digital Health reportable segment Adjusted EBITDA(1) decreased to $1.3 million in the first quarter of 2026 from $3.7 million in the first quarter of 2025 resulting from continued intentional infrastructure investments to drive and support a growing sales pipelineIn the first quarter of 2026, aggregate advanced imaging (MRI, CT and PET/CT) procedural volumes increased 19.7% and same-center advanced imaging procedural volumes increased 8.2% as compared with the first quarter of 2025Adjusting for unusual or one-time items in the quarter, Adjusted Diluted Loss Per Share(3) was $(0.28) for the first quarter of 2026; This compares with Adjusted Diluted Loss Per Share(3) of $(0.34) for the first quarter of 2025  RadNet revises full-year 2026 Imaging Center guidance levels with increases to Revenue, Adjusted EBITDA(1) and Free Cash Flow(2) and reaffirms all Digital Health guidance ranges
LOS ANGELES, May 10, 2026 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, cost-effective, fixed-site outpatient diagnostic imaging services through a network of 435 outpatient imaging centers and a premier developer of radiology digital health solutions, today reported financial results for its first quarter of 2026.

Dr. Howard Berger, President and Chief Executive Officer of RadNet, commented, “After being impacted by severe winter weather conditions in the Northeast during January and February which reduced Revenue and Adjusted EBITDA(1) by an estimated $13 million and $9 million, respectively, our business strongly rebounded in March, resulting in a Total Company Revenue increase of 22.1% and a Total Company Adjusted EBITDA(1) increase of 36.3% from last year’s first quarter. The record first quarter performance was driven by aggregate advanced imaging (MRI, CT and PET/CT) growth of 19.7% and same-center advanced imaging growth of 8.2% as compared with the first quarter of last year. The growth in MR, CT and PET/CT contributed to a 235 basis point shift in RadNet’s advanced imaging procedural volume mix (relative to routine imaging) as compared with the same quarter last year, increasing from 26.9% in last year’s first quarter to 29.3% in the first quarter of 2026. Imaging Center Adjusted EBITDA(1) margin increased by 52 basis points, after adjusting for lost Revenue and Adjusted EBITDA(1) from the severe winter weather in this year’s first quarter and the severe winter weather and California wildfires in last year’s first quarter.”

Dr. Berger continued, “On April 30th, we announced the commencement of a new health system joint venture with Trinity Health’s Saint Alphonsus Health System initially with five outpatient imaging centers in Boise, Idaho. In conjunction with this new partnership, various modules of DeepHealth OS as well as AI-powered solutions for radiologist reporting, patient engagement and clinical interpretation will be implemented. This relationship is a blueprint for future health system partnerships, where RadNet can bring all of its operational, clinical and digital workflow solutions to bear to streamline the patient journey and improve medical care and outcomes. As a result of the strong operating trends during the first quarter which have continued through early May, we are increasing 2026 Imaging Center guidance for Revenue, Adjusted EBITDA(1) and Free Cash Flow(2).”

“The Digital Health division continues to gain momentum, which was further advanced with the March 2, 2026 acquisition of Gleamer SAS in France. DeepHealth’s clinical AI portfolio now includes interpretive solutions in virtually all imaging modalities. We estimate that by the end of this year, over 70% of RadNet studies could be running through clinical AI, and we expect that all of RadNet’s radiologist reports will be processed through DeepHealth’s Reporting Pro AI-powered auto-impression/summarization engine. When fully implemented, these initiatives should result in significant enhancement to patient care and workflow productivity intended to achieve a measurable improvement to RadNet’s operating expenses. Furthermore, the Digital Health sales pipeline with third-party customers continued to build during the first quarter, during which we signed over $16 million (Total Contract Value) of new DeepHealth business. These contracts span the full breadth of DeepHealth products including clinical AI, operating and diagnostic workflow and TechLive solutions,” added Dr. Berger.

“RadNet’s balance sheet continues to be among the strongest in the diagnostic imaging industry. At quarter end, which reflected the acquisition of Gleamer and recent imaging center transactions, we had a cash balance of $455.3 million and a leverage ratio of Net Debt to Adjusted EBITDA(1) of slightly below 2.0. Financial leverage and liquidity will continue to be carefully managed to maintain optimal future operating flexibility,” concluded Dr. Berger.

Financial Results

For the first quarter of 2026, RadNet reported Total Company Revenue of $575.6 million and Adjusted EBITDA(1) of $63.3 million. Revenue increased $104.2 million (or 22.1%) and Adjusted EBITDA(1) increased $16.9 million (or 36.3%) as compared with the first quarter of 2025.

For the first quarter of 2026, RadNet reported Digital Health Revenue (inclusive of intersegment revenue) of $29.1 million and Adjusted EBITDA(1) of $1.3 million. Revenue increased $9.9 million (or 51.5%) and Adjusted EBITDA(1) decreased $2.4 million as compared with the first quarter of 2025. At March 31, 2026, Annual Recurring Revenue(4) (ARR) for Digital Health was $96.9 million, as compared with $49.8 million as of March 31, 2025.

There were a number of unusual or one-time items impacting the first quarter including: $0.9 million expense related to leases for de novo facilities under construction that have yet to open their operations; $3.5 million of acquisition transaction costs; $2.6 million loss on the sale and disposal of equipment; $1.5 million of severance costs; $2.8 million change in contingent consideration related to past acquisitions; and $4.6 million of non-capitalized research and development expenses with respect to DeepHealth Cloud OS and generative AI. Adjusting for the above items, Total Company Adjusted Loss(3) was $21.6 million and diluted Adjusted Loss Per Share(3) was $(0.28) for the first quarter of 2026. This compares with Total Company Adjusted Loss(3) of $25.2 million and diluted Adjusted Loss Per Share(3) of $(0.34) during the first quarter of 2025.

Unadjusted for unusual or one-time items impacting the first quarter of 2026, Total Company Net Loss for the first quarter of 2026 was $33.5 million as compared with a Total Company Net Loss of $37.9 million for the first quarter of 2025. Net Loss Per Share for the first quarter of 2026 was $(0.43), compared with a Net Loss per share of $(0.51) in the first quarter of 2025, based upon a weighted average number of diluted shares outstanding of 77.1 million shares in 2026 and 74.4 million shares in 2025.

For the first quarter of 2026, as compared with the prior year’s first quarter, MRI volume increased 20.3%, CT volume increased 17.7% and PET/CT volume increased 35.2% on a systemwide basis (including unconsolidated joint venture centers). Overall volume, taking into account routine imaging exams, inclusive of x-ray, ultrasound, mammography and other exams, increased 10.1% over the prior year’s first quarter. On a same-center systemwide basis, including only those centers which were part of RadNet for both the first quarters of 2026 and 2025, MRI volume increased 10.0%, CT volume increased 4.7% and PET/CT volume increased 14.7%. Overall same-center volume, taking into account routine imaging exams, inclusive of x-ray, ultrasound, mammography and other exams, increased 2.4% over the prior year’s same quarter.

2026 Revised Guidance

RadNet amends its previously announced guidance levels as follows:

Imaging Center Segment

  Original
Guidance Range
 Revised
Guidance Range   Total Net Revenue$2,325 - $2,375 million$2,355 - $2,405 millionAdjusted EBITDA(1)$335 - $348 million$340 - $353 millionCapital Expenditures(a)$165 - $175 million$165 - $175 millionCash Interest Expense(b)$45 - $50 million$45 - $50 millionFree Cash Flow(2)$105 - $115 million$112 - $122 million (a)   Net of proceeds from the sale of equipment and New Jersey Imaging Network capital expenditures.
(b)   Net of payments from counterparties on interest rate swaps and interest income from our cash balance recorded in Other Income.

Digital Health Segment

  Original
Guidance Range
 Revised
Guidance Range   Total Net Revenue$135 - $145 million$135 - $145 million   Adjusted EBITDA(1) Before Non-Capitalized R&D - DeepHealth Cloud OS & Generative AI$10 - $12 million$10 - $12 million   Non-Capitalized R&D - DeepHealth Cloud OS & Generative AI$17 - $19 million$17 - $19 million   Capital Expenditures$9 - $12 million$9 - $12 million   Free Cash Flow(2) Before Non-Capitalized R&D - DeepHealth Cloud OS & Generative AI$(1) - $3 million$(1) - $3 million   Free Cash Flow(2) After Non-Capitalized R&D - DeepHealth Cloud OS & Generative AI$(17) - $(19) million$(17) - $(19) million    Financial Results Conference Call

Dr. Howard Berger, President and Chief Executive Officer, and Mark Stolper, Executive Vice President and Chief Financial Officer, will host a conference call to discuss its first quarter 2026 results on Monday, May 11th, 2026 at 7:30 a.m. Pacific Time (10:30 a.m. Eastern Time).

Conference Call Details:

Date: Monday, May 11, 2026
Time: 10:30 a.m. Eastern Time
Dial In-Number: 844-744-1280
International Dial-In Number: 412-564-6465

It is recommended that participants dial in approximately 5 to 10 minutes prior to the start of the 10:30 a.m. call. There will also be simultaneous and archived webcasts available at https://viavid.webcasts.com/starthere.jsp?ei=1761306&tp_key=ea5d61284c or http://www.radnet.com under the “Investors” menu section and “News Releases” sub-menu of the website. An archived replay of the call will also be available and can be accessed by dialing 844-512-2921 from the U.S., or 412-317-6671 for international allers, and using the passcode 10208825.

About RadNet, Inc.

RadNet, Inc. is a leading national provider of freestanding, fixed-site diagnostic imaging services in the United States based on the number of locations and annual imaging revenue. RadNet has a network of owned and/or operated outpatient imaging centers. RadNet’s imaging center markets include Arizona, California, Delaware, Florida, Idaho, Indiana, Maryland, New Jersey, New York, Texas and Virginia. In addition, RadNet provides radiology information technology and artificial intelligence solutions marketed under the DeepHealth brand, teleradiology professional services and other related products and services to customers in the diagnostic imaging industry globally. Together with contracted radiologists, and inclusive of full-time and per diem employees and technologists, RadNet has over 11,000 team members. Learn more at radnet.com.

Forward Looking Statements

This press release contains “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements are expressions of our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, and anticipated future conditions, events and trends. Forward-looking statements can generally be identified by words such as: “anticipate,” “intend,” “plan,” “goal,” “seek,” “believe,” “project,” “estimate,” “expect,” “strategy,” “future,” “likely,” “may,” “should,” “will” and similar references to future periods.

Forward-looking statements are neither historical facts nor assurances of future performance. Because forward-looking statements relate to the future, they are inherently subject to uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not place undue reliance on any of these forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following:

the impact of a pandemic, significant deterioration in the broader economy, severe acts of nature or other exogenous factors on our business, suppliers, payors, customers, referral sources, partners, patients and employees;the availability and terms of capital to fund our business;our ability to service our indebtedness, make principal and interest payments as those payments become due and remain in compliance with applicable debt covenants, in addition to our ability to refinance such indebtedness on acceptable terms;changes in general economic conditions nationally and regionally in the markets in which we operate;the availability and terms of capital to fund the expansion of our business and improvements to our existing facilities;our ability to maintain our current credit rating and the impact on our funding costs and competitive position if we do not do so;our ability to acquire, develop, implement and monetize artificial intelligence algorithms and applications;volatility in interest and exchange rates, or credit markets;the adequacy of our cash flow and earnings to fund our current and future operations;changes in service mix, revenue mix and procedure volumes;delays in receiving payments for services provided;increased bankruptcies among our partner physicians or joint venture partners;the impact of the political environment and related developments on the current healthcare marketplace and on our business, including with respect to the future of the Affordable Care Act;the extent to which the ongoing implementation of healthcare reform, or changes in or new legislation, regulations or guidance, enforcement thereof by federal and state regulators or related litigation result in a reduction in coverage or reimbursement rates for our services, or other material impacts to our business;closures or slowdowns and changes in labor costs and labor difficulties, including stoppages affecting either our operations or our suppliers' abilities to deliver supplies needed in our facilities;the occurrence of hostilities, political instability or catastrophic events;the emergence or reemergence of and effects related to future pandemics, epidemics and infectious diseases; andnoncompliance by us with any privacy or security laws or any cybersecurity incident or other security breach by us or a third party involving the misappropriation, loss or other unauthorized use or disclosure of confidential information.With respect to mergers and acquisitions: (1) the termination of or occurrence of any event, change or other circumstances that could give rise to the termination of the merger or acquisition agreement or the inability to complete the proposed transaction on the anticipated terms and timetable, (2) the inability to complete the proposed transaction due to any applicable regulatory approval that may be required for the proposed transaction that is delayed, that is not obtained or that is obtained subject to conditions that are not anticipated, (3) the ability to recognize the anticipated benefits of the proposed transaction, which may be affected by, among other things, the ability to maintain relationships with its customers, patients, payers, physicians, and providers and retain its management and key employees, (4) the ability of RadNet following the proposed transaction to achieve the synergies contemplated by the proposed transaction or such synergies taking longer to realize than expected, (5) costs related to the proposed transaction, (6) the ability of RadNet following the proposed transaction to execute successfully its strategic plans, (7) the ability of RadNet following the proposed transaction to promptly and effectively integrate the target into its business, (8) the risk of litigation related to the proposed transaction, (9) the diversion of management's time and attention from ordinary course business operations to completion of the proposed transaction and integration matters, (10) the risk of legislative, regulatory, economic, competitive, and technological changes, (11) risks relating to the value of RadNet's securities to be issued in the proposed merger, and (12) the effect of the announcement, pendency or completion of the proposed transactions on the market price of RadNet’s common stock.
The foregoing review of important factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included elsewhere. Additional information concerning risks, uncertainties and assumptions can be found in RadNet's filings with the SEC, including the risk factors discussed in RadNet's most recent Annual Report on Form 10-K, as updated by its Quarterly Reports on Form 10-Q and future filings with the SEC.

Any forward-looking statement contained in this release is based on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that we may make from time to time, whether as a result of changed circumstances, new information, future developments or otherwise, except as required by applicable law.

Regulation G: GAAP and Non-GAAP Financial Information

This release contains certain financial information not reported in accordance with GAAP. The Company uses both GAAP and non-GAAP metrics to measure its financial results. The Company believes that, in addition to GAAP metrics, these non-GAAP metrics assist the Company in measuring its cash-based performance. The Company believes this information is useful to investors and other interested parties because it removes unusual and nonrecurring charges that occur in the affected period and provides a basis for measuring the Company's financial condition against other quarters. Such information should not be considered as a substitute for any measures calculated in accordance with GAAP, and may not be comparable to other similarly titled measures of other companies. Non-GAAP financial measures should not be considered in isolation from, or as a substitute for, financial information prepared in accordance with GAAP. Reconciliation of this information to the most comparable GAAP measures is included in this release in the tables which follow.

CONTACTS:

RadNet, Inc.

Mark Stolper, 310-445-2800

Executive Vice President and Chief Financial Officer

 RADNET, INC. AND SUBSIDIARIESCONDENSED CONSOLIDATED BALANCE SHEETS(IN THOUSANDS EXCEPT SHARE AND PER SHARE DATA)     March 31, 2026 December 31, 2025 (unaudited)  ASSETS   CURRENT ASSETS   Cash and Cash equivalents$455,339  $767,215 Accounts receivable 209,090   200,317 Due from affiliates 11,033   12,592 Prepaid expenses and other current assets 65,313   52,003 Total current assets 740,775   1,032,127 PROPERTY, EQUIPMENT AND RIGHT-OF-USE ASSETS   Property and equipment, net 862,057   807,702 Operating lease right-of-use assets 760,975   690,250 Total property, plant, equipment and right-of-use assets 1,623,032   1,497,952 OTHER ASSETS   Goodwill 1,094,699   907,663 Other intangible assets 253,481   148,508 Deferred financing costs 1,538   1,684 Investment in joint ventures 131,409   130,340 Deposits and other 40,455   40,289 Total Assets$3,885,389  $3,758,563     LIABILITIES AND EQUITY   CURRENT LIABILITIES   Accounts payable, accrued expenses and other$454,602  $422,029 Due to affiliates 75,960   70,104 Deferred revenue 11,975   7,272 Current operating lease liability 66,591   61,934 Current portion of notes payable 26,506   25,424 Total current liabilities 635,634   586,763 LONG-TERM LIABILITIES   Long-term finance lease liability 4,016   - Long-term operating lease liability 777,268   707,001 Notes payable, net of current portion 1,059,977   1,064,495 Deferred tax liability, net 34,150   21,903 Other non-current liabilities 21,632   22,515 Total liabilities 2,532,677   2,402,677 EQUITY   RadNet, Inc. stockholders' equity:   Common stock - $0.0001 value, 200,000,000 shares authorized; 78,545,837 and 77,399,615 shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively 8   8 Additional paid-in-capital 1,211,912   1,180,434 Accumulated other comprehensive loss (2,466)  4,885 Accumulated deficit (128,903)  (95,437)Total RadNet, Inc.'s Stockholders' equity: 1,080,551   1,089,890 Noncontrolling interests 272,161   265,996 Total Equity 1,352,712   1,355,886 Total liabilities and equity$3,885,389  $3,758,563      RADNET, INC. AND SUBSIDIARIESCONDENSED CONSOLIDATED STATEMENT OF OPERATIONS(IN THOUSANDS EXCEPT FOR SHARE AND PER SHARE DATA)(unaudited) Three Months Ended March 31,  2026   2025     REVENUE   Service fee revenue$545,218  $439,349 Revenue under capitation arrangements 30,413   32,050 Total service revenue 575,631   471,399 OPERATING EXPENSES   Cost of operations, excluding depreciation and amortization 550,512   453,480 Lease abandonment charges -   5,388 Depreciation and amortization 44,967   35,483 Loss (gain) on sale and disposal of equipment and other 2,591   402 Severance costs 1,464   747 Total operating expenses 599,534   495,500 INCOME (LOSS) FROM OPERATIONS (23,903)  (24,101)OTHER INCOME AND EXPENSES   Interest expense 17,657   17,239 Equity in earnings of joint ventures (3,825)  (2,599)Non-cash change in fair value of interest rate hedge -   2,106 Other (income) expenses (4,907)  (7,712)Total other (income) expenses 8,925   9,034 INCOME (LOSS) BEFORE INCOME TAXES (32,828)  (33,135)Provision for income taxes 8,096   3,398 NET INCOME (LOSS) (24,732)  (29,737)Net income (loss) attributable to noncontrolling interests 8,734   8,189 NET INCOME (LOSS) ATTRIBUTABLE TO RADNET, INC. COMMON STOCKHOLDERS$ (33,466) $ (37,926)    BASIC NET INCOME (LOSS) PER SHARE ATTRIBUTABLE TO RADNET, INC. COMMON STOCKHOLDERS$ (0.43) $ (0.51)    DILUTED NET INCOME (LOSS) PER SHARE ATTRIBUTABLE TO RADNET, INC. COMMON STOCKHOLDERS$ (0.43) $ (0.51)WEIGHTED AVERAGE SHARES OUTSTANDING   Basic 77,057,835   74,382,356 Diluted 77,057,835   74,382,356      RADNET, INC. AND SUBSIDIARIESCONDENSED CONSOLIDATED STATEMENTS OF CASHFLOWS(IN THOUSANDS)(unaudited) Three Months Ended March 31,  2026   2025 CASH FLOWS FROM OPERATING ACTIVITIES   Net loss$(24,732) $(29,737)Adjustments to reconcile net loss to net cash provided by operating activities:   Depreciation and amortization 44,967   35,483 Noncash operating lease expense 16,298   14,431 Equity in earnings of joint ventures, net of dividends (1,069)  (2,599)Amortization of deferred financing costs and loan discount 779   728 Loss on sale and disposal of equipment 2,591   402 Lease abandonment charges -   5,388 Amortization of cash flow hedge -   1,033 Non-cash change in fair value of interest rate swap -   2,106 Stock-based compensation 31,375   28,494 Change in fair value of contingent consideration (2,764)  - Changes in operating assets and liabilities, net of assets acquired and liabilities assumed in purchase transactions:   Accounts receivable 9,375   (14,306)Other current assets (6,172)  (7,206)Other assets (660)  (1,691)Deferred taxes (9,099)  5,137 Operating leases (13,299)  (21,968)Deferred revenue 234   128 Accounts payable, accrued expenses and other 31,148   25,658 Net cash provided by operating activities 78,972   41,481 CASH FLOWS FROM INVESTING ACTIVITIES   Purchase of imaging facilities and other acquisitions, net of cash acquired (304,151)  (3,794)Purchase of property and equipment and other (69,932)  (48,833)Proceeds from sale of equipment 277   23 Equity contributions in existing and purchase of interest in joint ventures -   (4,147)Collection of notes receivable 2,833   - Net cash used in investing activities (370,973)  (56,751)CASH FLOWS FROM FINANCING ACTIVITIES   Principal payments on notes and leases payable (9,953)  (1,718)Payments on Term Loan Debt (5,252)  (5,000)Distributions paid to noncontrolling interests (2,402)  (913)Proceeds from issuance of common stock upon exercise of options 103   121 Net cash used in financing activities (17,504)  (7,510)EFFECT OF EXCHANGE RATE CHANGES ON CASH (2,371)  83 NET DECREASE IN CASH AND CASH EQUIVALENTS (311,876)  (22,697)CASH AND CASH EQUIVALENTS, beginning of period 767,215   740,020 CASH AND CASH EQUIVALENTS, end of period 455,339   717,323     SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION   Cash paid during the period for interest$17,073  $18,010 Cash paid during the period for income taxes$519  $272      RADNET, INC. AND SUBSIDIARIESRECONCILIATION OF GAAP NET INCOME ATTRIBUTABLE TO RADNET, INC. COMMON SHAREHOLDERS TO ADJUSTED EBITDA(IN THOUSANDS) Three Months Ended March 31,  2026   2025     Net income (loss) attributable to Radnet, Inc. common stockholders$(33,466) $(37,926)Income taxes (8,096)  (3,398)Interest expense 17,657   17,239 Severance costs 1,464   747 Depreciation and amortization 44,967   35,483 Non-cash employee stock-based compensation 31,376   28,494 Loss (gain) on sale and disposal of equipment and other 2,591   402 Non-cash change in fair value of interest rate hedge -   2,106 Other expenses (income) (4,907)  (7,712)Non-Capitalized R&D - DeepHealth Cloud OS & Generative AI 4,560   3,562 Lease abandonment charges -   5,388 Non-cash change to contingent consideration 2,764   - Non-operational rent expenses 900   1,342 Acquisition transaction costs 3,454   672     Adjusted EBITDA - Radnet, Inc.$63,264  $46,399     NOTE   Adjusted EBITDA - Imaging Center Segment 61,961   42,688 Adjusted EBITDA - Digital Health Segment 1,303   3,711      PAYMENTS BY PAYOR CLASS              First Quarter
    2026
       Commercial Insurance 57.4%  Medicare 23.8%  Capitation 5.3%  Medicaid 2.4%  Workers Compensation/Personal Injury2.1%  Other* 8.9%  Total 100.0%       * Includes management fee, Digital Health unit and Heart Lung Health revenue.                 RADNET PAYMENTS BY MODALITY                       First Quarter Full Year Full Year Full Year   2026
 2025
 2024
 2023
           MRI 37.6% 37.7% 37.1% 36.8% CT 15.1% 15.6% 15.9% 16.8% PET/CT 10.4% 8.8% 7.2% 6.4% X-ray 5.2% 5.5% 6.0% 6.5% Ultrasound 13.7% 13.5% 13.6% 12.9% Mammography 14.7% 15.6% 16.4% 16.0% Nuclear Medicine 0.9% 0.9% 1.0% 0.8% Other 2.5% 2.5% 2.7% 3.9%   100.0% 100.0% 100.0% 100.0%            PROCEDURES BY MODALITY*           First Quarter First Quarter    2026 2025        MRI 538,043 447,330 CT  319,201 271,170 PET/CT 27,572 20,389 Nuclear Medicine10,395 9,577 Ultrasound 718,006 656,427 Mammography504,761 476,378 X-ray and Other902,977 861,702        Total
 3,020,955 2,742,973               * Volumes include wholy owned and joint venture centers.         RADNET, INC. AND SUBSIDIARIESSCHEDULE OF ADJUSTED EARNINGS AND EARNINGS PER SHARE (3)(IN THOUSANDS EXCEPT SHARE DATA)(unaudited)                              Three Months Ended        March 31,         2026  2025(iv)           NET LOSS INCOME ATTRIBUTABLE TO RADNET, INC.     COMMON STOCKHOLDERS  $(33,466) $(37,926)             Add Non-cash change in fair value of interest rate hedges (i) -   2,106   Add Non-operational rent expenses (iii)  900   1,342   Add Acquisition transaction costs   3,454   672   Add loss on sale and disposal of equipment and other 2,591   402   Add Severance costs    1,464   747   Add Lease abandonment charges   -   5,388   Add Change to contingent consideration  2,764   -   Add Non-capitalized R&D - DeepHealth cloud OS & generative AI 4,560   3,562   Total adjustments - loss (gain)   15,733   14,219   Subtract tax impact of Adjustments (ii)   (3,880)  (1,459)  Tax effected impact of adjustments   11,853   12,760            TOTAL ADJUSTMENT TO NET INCOME (LOSS) ATTRIBUTABLE     TO RADNET, INC. COMMON SHAREHOLDERS 11,853   12,760            ADJUSTED NET LOSS ATTRIBUTABLE TO RADNET, INC. (21,613)  (25,166)  COMMON STOCKHOLDERS                WEIGHTED AVERAGE SHARES OUTSTANDING     Diluted     77,057,835   74,382,356            ADJUSTED DILUTED NET LOSS PER SHARE     ATTRIBUTABLE TO RADNET, INC. COMMON STOCKHOLDERS$(0.28) $(0.34)           (i) Impact from the change in fair value of the hedges during the quarter. Excludes the amortization  of the accumulation of the changes in fair value out of Other Comprehensive Income that existed prior to the hedgesbecoming ineffective.      (ii) Tax effected using 10.26% and 24.66% blended federal and state effective tax rate for the first quarter of 2025 and 2026, respectively.(iii) Represents rent expense associated with de novo sites under construction prior to them becoming operational. (iv) Adjusted from what was reported during last year's fourth quarter for an additional addback of $402,000 Loss on the Sale andDisposal of Equipment and Other and $747,000 Severance Costs               Footnotes

(1) The Company defines Adjusted EBITDA as earnings before interest, taxes, depreciation and amortization, each from continuing operations and adjusted for losses or gains on the sale of equipment, other income or loss, debt extinguishments and non-cash equity compensation. Adjusted EBITDA includes equity earnings in unconsolidated operations and subtracts allocations of earnings to non-controlling interests in subsidiaries, and is adjusted for non-cash or extraordinary and one-time events taken place during the period.

Adjusted EBITDA is reconciled to its nearest comparable GAAP financial measure. Adjusted EBITDA is a non-GAAP financial measure used as analytical indicator by RadNet management and the healthcare industry to assess business performance, and is a measure of leverage capacity and ability to service debt. Adjusted EBITDA should not be considered a measure of financial performance under GAAP, and the items excluded from Adjusted EBITDA should not be considered in isolation or as alternatives to net income, cash flows generated by operating, investing or financing activities or other financial statement data presented in the consolidated financial statements as an indicator of financial performance or liquidity. As Adjusted EBITDA is not a measurement determined in accordance with GAAP and is therefore susceptible to varying methods of calculation, this metric, as presented, may not be comparable to other similarly titled measures of other companies.

(2) As noted above, the Company defines Free Cash Flow as Adjusted EBITDA less total Capital Expenditures (whether completed with cash or financed) and Cash Interest paid. Free Cash Flow is a non-GAAP financial measure. The Company uses Free Cash Flow because the Company believes it provides useful information for investors and management because it measures our capacity to generate cash from our operating activities. Free Cash Flow does not represent total cash flow since it does not include the cash flows generated by or used in financing activities. In addition, our definition of Free Cash Flow may differ from definitions used by other companies.

Free Cash Flow should not be considered a measure of financial performance under GAAP, and the items excluded from Adjusted EBITDA should not be considered in isolation or as alternatives to net income, cash flows generated by operating, investing or financing activities or other financial statement data presented in the consolidated financial statements as an indicator of financial performance or liquidity. As Adjusted EBITDA is not a measurement determined in accordance with GAAP and is therefore susceptible to varying methods of calculation, this metric, as presented, may not be comparable to other similarly titled measures of other companies.

(3) The Company defines Adjusted Earnings (Loss) Per Share as net income or loss attributable to RadNet, Inc. common stockholders and excludes losses or gains on the disposal of equipment, loss on debt extinguishments, bargain purchase gains, severance costs, loss on impairment, loss or gain on swap valuation, gain on extinguishment of debt, unusual or non-recurring entries that impact the Company’s tax provision and any other non-recurring or unusual transactions recorded during the period.

Adjusted Earnings (Loss) Per Share is reconciled to its nearest comparable GAAP financial measure. Adjusted Earnings (Loss) Per Share is a non-GAAP financial measure used as analytical indicator by RadNet management and the healthcare industry to assess business performance. Adjusted Earnings Per Share should not be considered a measure of financial performance under GAAP, and the items excluded from Adjusted Earnings Per Share should not be considered in isolation or as alternatives to net income, cash flows generated by operating, investing or financing activities or other financial statement data presented in the consolidated financial statements as an indicator of financial performance or liquidity. As Adjusted Earnings Per Share is not a measurement determined in accordance with GAAP and is therefore susceptible to varying methods of calculation, this metric, as presented, may not be comparable to other similarly titled measures of other companies.

(4) The Company defines Annual Recurring Revenue (ARR) as a key subscription economy metric representing the predictable, normalized annualized value of contracted recurring revenue generated from customers from active customer contracts. ARR includes subscription fees, recurring support fees, and contracted usage charges and excludes one-time, non-recurring fees such as, implementation, hardware sales, professional services, consulting and one-off training. ARR is a non-GAAP measure and does not represent GAAP revenue recognized over time.

MarketBeat Instant News Alerts Trending News All MarketBeat Instant News Alerts Sort By

Time Frame

Alert Type

Keywords

Page 1 of 322

Get 30 Days of MarketBeat All Access for Free

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools.

Start Your 30-Day Trial

Sign in to your free account to enjoy these benefits

In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer.

Jefferies, an investment banking and capital management firm, has updated its ‘Franchise Picks' list, which features the company's highest-conviction ‘Buy' rated stocks.

Investors in RadNet, Inc. (RDNT - Free Report) need to pay close attention to the stock based on moves in the options market lately. That is because the June 18, 2026 $40.00 Call had some of the highest implied volatility of all equity options today.

What is Implied Volatility?Implied volatility shows how much movement the market is expecting in the future. Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction or the other. It could also mean there is an event coming up soon that may cause a big rally or a huge sell-off. However, implied volatility is only one piece of the puzzle when putting together an options trading strategy.

What do the Analysts Think?Clearly, options traders are pricing in a big move for RadNet shares, but what is the fundamental picture for the company? Currently, RadNet is a Zacks Rank #3 (Hold) in the Medical - Outpatient and Home Healthcare industry that ranks in the Top 25% of our Zacks Industry Rank. Over the last 60 days, our Zacks Consensus Estimate for the current quarter has moved from 24 cents per share to 18 cents in that period.

Given the way analysts feel about RadNet right now, this huge implied volatility could mean there’s a trade developing. Oftentimes, options traders look for options with high levels of implied volatility to sell premium. This is a strategy many seasoned traders use because it captures decay. At expiration, the hope for these traders is that the underlying stock does not move as much as originally expected.

June 03, 2026 08:00 ET  | Source: RadNet, Inc.

LOS ANGELES, June 03, 2026 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT) (“RadNet”), a national leader in providing high-quality, cost-effective, fixed-site outpatient diagnostic imaging services through a network of outpatient imaging centers and a premier developer of radiology digital health solutions, today announced that it seeks to secure an incremental term loan in the aggregate principal amount of $200 million (the “Proposed 2026 Incremental Term Loan”) pursuant to a proposed amendment (the “Proposed Amendment”) to its Third Amended and Restated First Lien Credit and Guaranty Agreement, as amended (the “Existing Credit Agreement” and, the transaction, the “Loan Transaction”).

If consummated, the Proposed 2026 Incremental Term Loan would be added to and form a part of the existing term loan under the Existing Credit Agreement (the “Existing Term Loan”). The Proposed 2026 Incremental Term Loan would mature on April 18, 2031—coincident with the maturity date of the Existing Term Loan under the Existing Credit Agreement.

The proceeds of the Proposed 2026 Incremental Term Loan are expected to be used to finance future acquisitions, organic expansion initiatives, health system partnerships and for other general corporate purposes, providing RadNet with additional flexibility to pursue strategic growth opportunities across its national imaging center network and technology platforms.

Mark Stolper, Executive Vice President and Chief Financial Officer of RadNet, commented: “We are seeking to opportunistically and proactively raise additional funds to support the future growth of our business. While the consummation of the Loan Transaction is subject to customary market and other conditions, if successful, we expect to consummate the Loan Transaction towards the middle of this month.”

This press release does not constitute an offer to sell or a solicitation of an offer to buy any securities of RadNet and shall not constitute an offer, solicitation or sale in any jurisdiction in which such an offer, solicitation or sale would be unlawful prior to the registration and qualification under the securities laws of such state or jurisdiction.

About RadNet, Inc.

RadNet, Inc. is a leading national provider of freestanding, fixed-site diagnostic imaging services in the United States based on the number of locations and annual imaging revenue. RadNet has a network of owned and/or operated outpatient imaging centers. RadNet’s imaging center markets include Arizona, California, Delaware, Florida, Idaho, Indiana, Maryland, New Jersey, New York, Texas and Virginia. In addition, RadNet provides radiology information technology and artificial intelligence solutions marketed under its DeepHealth brand and teleradiology professional services and other related products and services to customers in the diagnostic imaging industry globally. Together with contracted radiologists, and inclusive of full-time and per diem employees and technologists, RadNet has over 11,000 team members. Learn more at radnet.com.

Forward Looking Statements 

This press release contains “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements are expressions of RadNet’s current beliefs, expectations and assumptions regarding the future of RadNet’s business, future plans and strategies, projections, and anticipated future conditions, events and trends. Forward-looking statements can generally be identified by words such as: “anticipate,” “intend,” “plan,” “goal,” “seek,” “believe,” “project,” “estimate,” “expect,” “strategy,” “future,” “likely,” “may,” “should,” “will” and similar references to future periods. Forward-looking statements in this press release include, among others, statements RadNet makes regarding its ability to reach mutually agreeable terms for the Proposed Amendment, to amend the Existing Credit Agreement and to consummate the Loan Transaction; the timing and ultimate terms of any such amendment and consummation; and its expected use of proceeds from the Loan Transaction.

Forward-looking statements are neither historical facts nor assurances of future performance. Because forward-looking statements relate to the future, they are inherently subject to uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of RadNet’s control, which may cause actual events to be materially different from those expressed or implied herein. Therefore, you should not place undue reliance on any of these forward-looking statements. Important factors that could impact RadNet’s ability to amend the Existing Credit Agreement and consummate the Loan Transaction include, among others, the following:

a decline or anticipated decline in RadNet’s operating results or financial position, as a result of operational issues, regulatory changes, litigation, casualty loss, or other factors;changes in general economic conditions nationally and regionally in the markets in which RadNet operates;volatility in interest and exchange rates, or credit markets;the occurrence of hostilities, political instability or catastrophic events; andthe emergence or reemergence of and effects related to future pandemics, epidemics and infectious diseases.
Any forward-looking statement contained in this press release is based on information currently available to RadNet and speaks only as of the date on which it is made. RadNet undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that it may make from time to time, whether as a result of changed circumstances, new information, future developments or otherwise, except as required by applicable law.

Contact:
RadNet, Inc.
Mark Stolper, 310-445-2800
Executive Vice President and Chief Financial Officer

June 10, 2026 16:05 ET  | Source: RadNet, Inc.

LOS ANGELES, June 10, 2026 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT) (“RadNet”), a national leader in providing high-quality, cost-effective, fixed-site outpatient diagnostic imaging services through a network of outpatient imaging centers and a premier developer of radiology digital health solutions, today announced that it has entered into Incremental Amendment No. 3 (the “Third Amendment”) to its Third Amended and Restated First Lien Credit and Guaranty Agreement, as amended (the “Existing Credit Agreement” and, as amended by the Third Amendment, the “Credit Agreement”).

Pursuant to the Third Amendment, certain term lenders under the Credit Agreement funded RadNet an incremental term loan in the aggregate principal amount of $250.0 million (the “2026 Incremental Term Loan”), which was added to and forms a part of the existing term loan under the Credit Agreement (the “Existing Term Loan,” together with the 2026 Incremental Term Loan, the “Term Loan”). The 2026 Incremental Term Loan will mature on April 18, 2031—coincident with the maturity date of the $958.7 million balance of the Existing Term Loan under the Existing Credit Agreement. Quarterly payments of principal on the Term Loan will be approximately $3.1 million compared to approximately $2.4 million prior to the entry of the Third Amendment.   The proceeds of the 2026 Incremental Term Loan are expected to be used to finance future acquisitions, organic expansion initiatives, health system partnerships and for other general corporate purposes.

In addition, with the successful completion of the Third Amendment, the interest rate on the Term Loan was reduced by 0.25% to, at RadNet’s election, either Term SOFR plus 2.00% or the alternate base rate plus 1.00%. In addition, the interest rate on RadNet’s existing $282 million revolving credit facility (currently undrawn upon) was reduced by 0.25%.   In connection with the Third Amendment, RadNet has provided call protection to the term loan lenders participating in the repricing of the Existing Term Loan for a period of six months following the Third Amendment.  

Mark Stolper, Executive Vice President and Chief Financial Officer of RadNet, commented, “We appreciate the continued support of Barclays and our other relationship banks and term loan lenders. This amendment provides us with additional flexibility to pursue strategic growth opportunities across RadNet’s national imaging center network and technology platforms, while reducing the interest rate on our credit facilities. The proceeds of approximately $250 million adds to the $455 million cash balance as of March 31, 2026, positioning us to advance our growth strategy and create long-term value for our stockholders.” 

This press release does not constitute an offer to sell or a solicitation of an offer to buy any securities of RadNet and shall not constitute an offer, solicitation or sale in any jurisdiction in which such an offer, solicitation or sale would be unlawful prior to the registration and qualification under the securities laws of such state or jurisdiction.

About RadNet, Inc.

RadNet, Inc. is a leading national provider of freestanding, fixed-site diagnostic imaging services in the United States based on the number of locations and annual imaging revenue. RadNet has a network of owned and/or operated outpatient imaging centers. RadNet’s imaging center markets include Arizona, California, Delaware, Florida, Idaho, Indiana, Maryland, New Jersey, New York, Texas and Virginia. In addition, RadNet provides radiology information technology and artificial intelligence solutions marketed under its DeepHealth brand and teleradiology professional services and other related products and services to customers in the diagnostic imaging industry globally. Together with contracted radiologists, and inclusive of full-time and per diem employees and technologists, RadNet has over 11,000 team members. Learn more at radnet.com.

Forward Looking Statements

This press release contains “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements are expressions of RadNet’s current beliefs, expectations and assumptions regarding the future of RadNet’s business, future plans and strategies, projections, and anticipated future conditions, events and trends. Forward-looking statements can generally be identified by words such as: “anticipate,” “intend,” “plan,” “goal,” “seek,” “believe,” “project,” “estimate,” “expect,” “strategy,” “future,” “likely,” “may,” “should,” “will” and similar references to future periods. Forward-looking statements in this press release include, among others, statements RadNet makes regarding its expected use of proceeds from the 2026 Incremental Term Loan and its ability and success in pursuing strategic growth opportunities.

Forward-looking statements are neither historical facts nor assurances of future performance. Because forward-looking statements relate to the future, they are inherently subject to uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of RadNet’s control, which may cause actual events to be materially different from those expressed or implied herein. Therefore, you should not place undue reliance on any of these forward-looking statements. Important factors that could impact RadNet’s expected use of proceeds from the 2026 Incremental Term Loan and its ability and success in pursuing strategic growth opportunities include, among others, the following:

a decline or anticipated decline in RadNet’s operating results or financial position, as a result of operational issues, regulatory changes, litigation, casualty loss, or other factors;changes in general economic conditions nationally and regionally in the markets in which RadNet operates;volatility in interest and exchange rates, or credit markets;the occurrence of hostilities, political instability or catastrophic events; andthe emergence or reemergence of and effects related to future pandemics, epidemics and infectious diseases. Any forward-looking statement contained in this press release is based on information currently available to RadNet and speaks only as of the date on which it is made. RadNet undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that it may make from time to time, whether as a result of changed circumstances, new information, future developments or otherwise, except as required by applicable law.

Contact:
RadNet, Inc.
Mark Stolper, 310-445-2800
Executive Vice President and Chief Financial Officer